D H Thamm

Summary

Affiliation: Colorado State University
Country: USA

Publications

  1. pmc GS-9219/VDC-1101--a prodrug of the acyclic nucleotide PMEG has antitumor activity in spontaneous canine multiple myeloma
    Douglas H Thamm
    Flint Animal Cancer Center, Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, 300 W, Drake Rd, Fort Collins, CO 80523 1620, USA
    BMC Vet Res 10:30. 2014
  2. pmc DNA repair deficiency as a susceptibility marker for spontaneous lymphoma in golden retriever dogs: a case-control study
    Douglas H Thamm
    Flint Animal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado, United States of America
    PLoS ONE 8:e69192. 2013
  3. doi Masitinib as a chemosensitizer of canine tumor cell lines: a proof of concept study
    D H Thamm
    The Animal Cancer Center, Colorado State University, 300 West Drake Road, Fort Collins, CO 80523 1620, USA
    Vet J 191:131-4. 2012
  4. pmc Evaluation of prognostic markers for canine mast cell tumors treated with vinblastine and prednisone
    Joshua D Webster
    Comparative Medicine and Integrative Biology Program, College of Veterinary Medicine, Michigan State University, East Lansing, MI, USA
    BMC Vet Res 4:32. 2008
  5. ncbi Biological and molecular characterization of a canine hemangiosarcoma-derived cell line
    Douglas H Thamm
    Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin Madison, 53706, USA
    Res Vet Sci 81:76-86. 2006
  6. doi RT-PCR-based tyrosine kinase display profiling of canine melanoma: IGF-1 receptor as a potential therapeutic target
    Douglas H Thamm
    The Animal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado 80523 1620, USA
    Melanoma Res 20:35-42. 2010
  7. doi Serum vascular endothelial growth factor concentrations and postsurgical outcome in dogs with osteosarcoma
    D H Thamm
    Department of Clinical Sciences, Animal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523 1620, USA
    Vet Comp Oncol 6:126-32. 2008
  8. doi Cyclooxygenase-2 expression in equine tumors
    D H Thamm
    Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523 1620, USA
    Vet Pathol 45:825-8. 2008
  9. doi Preclinical investigation of PEGylated tumor necrosis factor alpha in dogs with spontaneous tumors: phase I evaluation
    Douglas H Thamm
    Animal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado 80523, USA
    Clin Cancer Res 16:1498-508. 2010
  10. ncbi Systemic administration of an attenuated, tumor-targeting Salmonella typhimurium to dogs with spontaneous neoplasia: phase I evaluation
    Douglas H Thamm
    Department of Medical Sciences and Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin Madison, USA
    Clin Cancer Res 11:4827-34. 2005

Collaborators

Detail Information

Publications51

  1. pmc GS-9219/VDC-1101--a prodrug of the acyclic nucleotide PMEG has antitumor activity in spontaneous canine multiple myeloma
    Douglas H Thamm
    Flint Animal Cancer Center, Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, 300 W, Drake Rd, Fort Collins, CO 80523 1620, USA
    BMC Vet Res 10:30. 2014
    ..Given the similarity in lineage between lymphoma and MM, we hypothesized that VDC-1101 would be active against MM...
  2. pmc DNA repair deficiency as a susceptibility marker for spontaneous lymphoma in golden retriever dogs: a case-control study
    Douglas H Thamm
    Flint Animal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado, United States of America
    PLoS ONE 8:e69192. 2013
    ..These studies set the stage for larger confirmatory studies, as well as candidate-based approaches to probe specific genetic susceptibility factors. ..
  3. doi Masitinib as a chemosensitizer of canine tumor cell lines: a proof of concept study
    D H Thamm
    The Animal Cancer Center, Colorado State University, 300 West Drake Road, Fort Collins, CO 80523 1620, USA
    Vet J 191:131-4. 2012
    ..The findings justify further investigation into those combinations that may potentially yield therapeutic benefit...
  4. pmc Evaluation of prognostic markers for canine mast cell tumors treated with vinblastine and prednisone
    Joshua D Webster
    Comparative Medicine and Integrative Biology Program, College of Veterinary Medicine, Michigan State University, East Lansing, MI, USA
    BMC Vet Res 4:32. 2008
    ..Disease-free intervals (DFI) and overall survival times (OS) of dogs with similar pretreatment prognostic indices postoperatively treated with chemotherapy were compared to dogs treated with surgery alone...
  5. ncbi Biological and molecular characterization of a canine hemangiosarcoma-derived cell line
    Douglas H Thamm
    Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin Madison, 53706, USA
    Res Vet Sci 81:76-86. 2006
    ....
  6. doi RT-PCR-based tyrosine kinase display profiling of canine melanoma: IGF-1 receptor as a potential therapeutic target
    Douglas H Thamm
    The Animal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado 80523 1620, USA
    Melanoma Res 20:35-42. 2010
    ..In conclusion, this study suggests that similar TKs are expressed in human and canine melanoma, and shows potential antitumor effects of IGF-1R inhibition in CMM...
  7. doi Serum vascular endothelial growth factor concentrations and postsurgical outcome in dogs with osteosarcoma
    D H Thamm
    Department of Clinical Sciences, Animal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523 1620, USA
    Vet Comp Oncol 6:126-32. 2008
    ..These data support a role for VEGF in the development or progression of metastatic disease in dogs with OSA. The VEGF concentration in tested sera was not a major determinant of ex vivo canine EC proliferation in this study...
  8. doi Cyclooxygenase-2 expression in equine tumors
    D H Thamm
    Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523 1620, USA
    Vet Pathol 45:825-8. 2008
    ..There were no differences in expression between anatomic sites. In conclusion, most equine SCC and many melanomas appear to express COX-2 and thus could respond to COX-2 inhibitor therapy...
  9. doi Preclinical investigation of PEGylated tumor necrosis factor alpha in dogs with spontaneous tumors: phase I evaluation
    Douglas H Thamm
    Animal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado 80523, USA
    Clin Cancer Res 16:1498-508. 2010
    ..This study characterized toxicity, biological effect, and antitumor activity of PEG-TNF in pet dogs with spontaneous cancer...
  10. ncbi Systemic administration of an attenuated, tumor-targeting Salmonella typhimurium to dogs with spontaneous neoplasia: phase I evaluation
    Douglas H Thamm
    Department of Medical Sciences and Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin Madison, USA
    Clin Cancer Res 11:4827-34. 2005
    ....
  11. pmc Doxorubicin and cyclophosphamide for the treatment of canine lymphoma: a randomized, placebo-controlled study
    J C Lori
    Animal Cancer Center, Colorado State University College of Veterinary Medicine, Fort Collins, CO 80523 1620, USA
    Vet Comp Oncol 8:188-95. 2010
    ..Despite a numeric improvement in outcome in cyclophosphamide treated dogs, the addition of cyclophosphamide did not result in statistically improved response rate, PFI or ST...
  12. doi Increased monocyte chemotactic protein-1 concentration and monocyte count independently associate with a poor prognosis in dogs with lymphoma
    J A Perry
    Animal Cancer Center, Department of Clinical Sciences, Colorado State University, Fort Collins, CO 80523, USA
    Vet Comp Oncol 9:55-64. 2011
    ..The mechanisms underlying these observations remain to be determined...
  13. ncbi Evaluation of a 15-week CHOP protocol for the treatment of canine multicentric lymphoma
    J H Burton
    Animal Cancer Center, Department of Clinical Sciences, Colorado State University, Fort Collins, CO, USA
    Vet Comp Oncol 11:306-15. 2013
    ..Future studies should focus on individual patient dose optimization. ..
  14. doi Clinical and immunomodulatory effects of toceranib combined with low-dose cyclophosphamide in dogs with cancer
    L Mitchell
    Animal Cancer Center, Department of Clinical Sciences, Colorado State University, Fort Collins, CO 80523 1620, USA
    J Vet Intern Med 26:355-62. 2012
    ..The immunomodulatory effects of the TKI toceranib, as a single agent or in combination with metronomic CYC, have not been previously investigated in dogs...
  15. pmc Multicenter prospective trial of hypofractionated radiation treatment, toceranib, and prednisone for measurable canine mast cell tumors
    K S Carlsten
    Department of Clinical Sciences, Colorado State University, Fort Collins, CO, USA
    J Vet Intern Med 26:135-41. 2012
    ..Mast cell tumors (MCT) are common cutaneous tumors in dogs and when not amenable to surgical excision can present a therapeutic challenge. New treatment protocols for unresectable MCT are needed...
  16. doi Comparative analysis of survivin expression in untreated and relapsed canine lymphoma
    R B Rebhun
    Department of Clinical Sciences, Animal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523, USA
    J Vet Intern Med 22:989-95. 2008
    ..Survivin expression has been shown to be a negative prognostic factor in several cancers of humans, including B-cell non-Hodgkin's lymphoma...
  17. doi Low-dose cyclophosphamide selectively decreases regulatory T cells and inhibits angiogenesis in dogs with soft tissue sarcoma
    J H Burton
    Department of Clinical Sciences, Animal Cancer Center, Colorado State University, Fort Collins, CO 80523, USA
    J Vet Intern Med 25:920-6. 2011
    ..The effects of metronomic chemotherapy on Treg and tumor angiogenesis in dogs has not been investigated previously...
  18. doi Glucose transporter 1 expression in canine osteosarcoma
    J C Petty
    Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523 1678, USA
    Vet Comp Oncol 6:133-40. 2008
    ..As hypothesized, GLUT-1 is present in canine appendicular OSAs. A more objective evaluation of GLUT-1 and other proteins in the HIF-1alpha pathway may be warranted...
  19. doi Induction of VEGF by tepoxalin does not lead to increased tumour growth in a canine osteosarcoma xenograft
    J L Sottnik
    Department of Clinical Sciences, Animal Cancer Center, Colorado State University, 300 West Drake Road, Fort Collins, CO 80523, USA
    Vet Comp Oncol 9:118-30. 2011
    ..These data suggest that tepoxalin may moderately inhibit tumour growth and may be administered as an analgesic to tumour-bearing dogs...
  20. doi Dose-escalating vinblastine for the treatment of canine mast cell tumour
    K R Vickery
    The Animal Cancer Center, Colorado State University, Fort Collins, CO 80523 1620, USA
    Vet Comp Oncol 6:111-9. 2008
    ..Randomized prospective trials are necessary to establish whether dose escalation will translate into improved response rates when compared with the standard 2 mg m(-2) dosage...
  21. doi Interleukin-11 receptor alpha is expressed on canine osteosarcoma
    J L Sottnik
    Department of Clinical Sciences, Animal Cancer Center, Colorado State University, Fort Collins, CO, USA
    Vet Comp Oncol 8:96-102. 2010
    ..Cytotoxin-conjugated antibodies targeting IL-11Ralpha-mediated canine OSA cytotoxicity. Thus, canine OSA may be a valuable model for the evaluation of IL-11Ralpha directed therapies...
  22. doi Combination chemotherapy with continuous L-asparaginase, lomustine, and prednisone for relapsed canine lymphoma
    C F Saba
    Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin Madison, WI, USA
    J Vet Intern Med 23:1058-63. 2009
    ..In a previous study, we reported that remission was typically lost around the time L-asparaginase was discontinued...
  23. doi Impact of telomerase status on canine osteosarcoma patients
    K Kow
    Department of Clinical Science, Animal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, USA
    J Vet Intern Med 22:1366-72. 2008
    ..The purpose of the current study was to examine the telomerase status of a large number of OSA samples from dogs and determine if telomerase status can serve as a prognostic factor...
  24. doi Association of blood monocyte and lymphocyte count and disease-free interval in dogs with osteosarcoma
    J L Sottnik
    Department of Clinical Sciences, Animal Cancer Center, Colorado State University, Fort Collins, CO 80523, USA
    J Vet Intern Med 24:1439-44. 2010
    ..Identification of biomarkers that predict outcomes in dogs with osteosarcoma (OSA) would be valuable to veterinarians and owners. Leukocyte numbers in peripheral blood are associated with outcomes in some types of cancer in humans...
  25. doi Elevated serum thymidine kinase activity in canine splenic hemangiosarcoma*
    D H Thamm
    Animal Cancer Center, Department of Clinical Sciences, Colorado State University, Fort Collins, CO 80523, USA
    Vet Comp Oncol 10:292-302. 2012
    ..When interval thresholds of <1.55 and >7.95 U/L were used together, diagnostic utility was increased. Serum TK1 evaluation may help to discriminate between benign disease and HSA in dogs with hemoabdomen and a splenic mass...
  26. ncbi Outcome and prognostic factors following adjuvant prednisone/vinblastine chemotherapy for high-risk canine mast cell tumour: 61 cases
    D H Thamm
    Department of Clinical Sciences, School of Veterinary Medicine, University of Wisconsin Madison 53704, USA
    J Vet Med Sci 68:581-7. 2006
    ..High-grade and mucocutaneous tumors had a worse outcome, and the use of prophylactic nodal irradiation appeared to improve outcome in this group of dogs...
  27. ncbi Epidermal growth factor enhances the malignant phenotype in canine mammary carcinoma cell lines
    K C Kennedy
    The Animal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, USA
    Vet Comp Oncol 9:196-206. 2011
    ..In conclusion, EGF stimulates multiple features promoting the malignant phenotype in CMT. Thus, CMT may be an important translational model for the investigation of novel EGFR-directed therapies...
  28. ncbi Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine model
    D M Vail
    Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin, Madison 53706, USA
    Clin Cancer Res 4:1567-71. 1998
    ..We conclude that pyridoxine is effective in delaying the onset and severity of PPES in this canine model...
  29. doi Pharmacokinetic modeling of doxorubicin pharmacokinetics in dogs deficient in ABCB1 drug transporters
    D L Gustafson
    Department of Clinical Sciences, and the Animal Cancer Center, Colorado State University, Fort Collins, CO 80523 1620, USA
    J Vet Intern Med 24:579-86. 2010
    ..The identification of dogs defective in ATP-binding cassette transporter B1 (ABCB1, MDR1) activity has prompted questions regarding pharmacokinetics (PK), efficacy and toxicity of ABCB1 substrates in these dogs...
  30. doi Comparison of carboplatin and doxorubicin-based chemotherapy protocols in 470 dogs after amputation for treatment of appendicular osteosarcoma
    L E Selmic
    Flint Animal Cancer Center, Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO
    J Vet Intern Med 28:554-63. 2014
    ..Many chemotherapy protocols have been reported for treatment of canine appendicular osteosarcoma (OSA), but outcome comparisons in a single population are lacking...
  31. ncbi Diagnostic accuracy of pre-treatment biopsy for grading soft tissue sarcomas in dogs
    J A Perry
    Department of Clinical Sciences, Colorado State University, Fort Collins, CO, USA Present address Aspen Meadow Veterinary Specialists in Longmont, Longmont, CO, USA
    Vet Comp Oncol 12:106-13. 2014
    ..Based on these data, needle-core biopsy appears to be similar in accuracy compared to open biopsy, however, grading determined by pre-treatment biopsy in general should be interpreted with caution. ..
  32. doi Phase II clinical evaluation of lomustine chemotherapy for feline vaccine-associated sarcoma
    C F Saba
    Departments of Small Animal Medicine and Surgery, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA
    Vet Comp Oncol 10:283-91. 2012
    ..Although these data support further investigation of lomustine for the treatment of VAS, safe, multidosing protocols must first be determined...
  33. pmc Development of a limited-sampling model for prediction of doxorubicin exposure in dogs
    L A Wittenburg
    Department of Clinical Sciences, Colorado State University Animal Cancer Center, Fort Collins, CO, USA
    Vet Comp Oncol 12:114-9. 2014
    ..This strategy could allow for refining of dosing variables and utilization of therapeutic drug monitoring to ensure optimized dosing. ..
  34. doi Lung tumor development and spontaneous regression in lambs coinfected with Jaagsiekte sheep retrovirus and ovine lentivirus
    S F Hudachek
    Animal Cancer Center, Veterinary Teaching Hospital, Colorado State University, 300 West Drake Road, Fort Collins, CO 80523 1620, USA
    Vet Pathol 47:148-62. 2010
    ..Overall, the genetic profile combined with the disease development data provides further important characterization of OPA and describes, for the first time, spontaneous regression of OPA tumors in experimentally infected sheep...
  35. ncbi Intralesional lipid-complexed cytokine/superantigen immunogene therapy for spontaneous canine tumors
    Douglas H Thamm
    Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin Madison, 2015 Linden Drive West, WI 53706, Madison, USA
    Cancer Immunol Immunother 52:473-80. 2003
    ..In conclusion, these studies suggests that intralesional L-SEA/cIL-2 immunotherapy is well tolerated, results in detectable transgene expression in canine tumors, and has antitumor activity in dogs with spontaneous STS...
  36. ncbi Aftershocks of cancer chemotherapy: managing adverse effects
    Douglas H Thamm
    The Animal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado 80523, USA
    J Am Anim Hosp Assoc 43:1-7. 2007
    ..This article presents guidelines for the management of chemotherapy-associated hematological and gastrointestinal disturbances, extravasation injury, and anaphylaxis...
  37. ncbi Preclinical study of dolastatin-10 in dogs with spontaneous neoplasia
    Douglas H Thamm
    Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin Madison, 2015 Linden Drive West, Madison, WI 53706, USA
    Cancer Chemother Pharmacol 49:251-5. 2002
    ..To evaluate the short-term adverse effects of administration of dolastatin-10 (Dol-10) to dogs with spontaneously occurring malignant tumors...
  38. pmc Systems biology approach to identification of biomarkers for metastatic progression in cancer
    Andrey A Ptitsyn
    Center for Bioinformatics, Department of Microbiology, Immunology and Pathology, Colorado State University, Colorado, USA
    BMC Bioinformatics 9:S8. 2008
    ..Previous studies of gene expression patterns in metastasis have concentrated on selection of a small number of "signature" biomarkers...
  39. ncbi c-Met tyrosine kinase receptor expression and function in human and canine osteosarcoma cells
    E Gregory MacEwen
    Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin Madison, Madison, Wisconsin 53706, USA
    Clin Exp Metastasis 20:421-30. 2003
    ..These data support the involvement of c-Met and HGF-SF in the growth and progression of human and canine OS, and may offer new targets for the development of therapeutic strategies for OS...
  40. ncbi Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma
    Barbara J Biller
    Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins 80523, USA
    J Vet Intern Med 21:113-20. 2007
    ..Therefore, we evaluated safety and immunologic responses to a novel tumor vaccine administered together with doxorubicin chemotherapy in dogs with different stages of HSA...
  41. ncbi Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma
    Laura D Garrett
    Kansas State University Veterinary Medical Teaching Hospital, USA
    J Vet Intern Med 16:704-9. 2002
    ..4% (5/53) needing hospitalization. The 6-month chemotherapy protocol based on CHOP with no maintenance phase provides similar DFI and survival times when compared to a similar protocol with a prolonged maintenance phase...
  42. ncbi Carcinoma of the apocrine glands of the anal sac in dogs: 113 cases (1985-1995)
    Laurel E Williams
    Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27606, USA
    J Am Vet Med Assoc 223:825-31. 2003
    ..To characterize the signalment, clinical signs, biological behavior, and response to treatment of carcinoma of the apocrine glands of the anal sac in dogs...
  43. ncbi Imatinib mesylate inhibits platelet-derived growth factor activity and increases chemosensitivity in feline vaccine-associated sarcoma
    Rieko Katayama
    Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin Madison, 2015 Linden Drive West, Madison, WI 53706, USA
    Cancer Chemother Pharmacol 54:25-33. 2004
    ..These observations suggest that imatinib inhibits PDGFR tyrosine kinase activity in feline soft tissue sarcomas in vitro and inhibits tumor growth in a xenograft model...
  44. ncbi Plasma synthesis of carbon magnetic nanoparticles and immobilization of doxorubicin for targeted drug delivery
    Yonghui Ma
    Center for Plasma Aided Manufacturing, University of Wisconsin, Madison, WI 53706, USA
    J Biomater Sci Polym Ed 15:1033-49. 2004
    ..The in vitro antiproliferative activity of immobilized doxorubicin in the conjugates was demonstrated in tumor cell cytotoxicity assays. It is suggested that this CMNP-DOX system can be used for targeted drug-delivery systems...
  45. ncbi Cytotoxic chemotherapy: new players, new tactics
    David M Vail
    Animal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado 80523, USA
    J Am Anim Hosp Assoc 41:209-14. 2005
    ..This article describes the drug development process and how a new product eventually finds its way into clinical use. Some of the newer drugs and delivery techniques applied to small animals are reviewed...
  46. ncbi Does L-asparaginase influence efficacy or toxicity when added to a standard CHOP protocol for dogs with lymphoma?
    Valerie S MacDonald
    Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin Madison, Madison, WI, USA
    J Vet Intern Med 19:732-6. 2005
    ..Therefore, it may be more appropriate to reserve the use of L-ASP for treating relapse in dogs with lymphoma that have failed induction therapy...
  47. ncbi IGF-1 receptor contributes to the malignant phenotype in human and canine osteosarcoma
    E Gregory MacEwen
    Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin Madison, Madison, Wisconsin 53706, USA
    J Cell Biochem 92:77-91. 2004
    ..There is suggestive evidence that increasing receptor number may contribute to in vivo tumorigenesis. Additional studies are needed to determine how IGF-1/IGF-1R interactions contribute to the malignant phenotype of OS...
  48. doi GS-9219--a novel acyclic nucleotide analogue with potent antineoplastic activity in dogs with spontaneous non-Hodgkin's lymphoma
    Hans Reiser
    Department of Research and Development, Gilead Sciences, Inc, Foster City, California 94404, USA
    Clin Cancer Res 14:2824-32. 2008
    ..Our objective was to characterize the antiproliferative activity, pharmacokinetics, pharmacodynamics, and safety of GS-9219...
  49. ncbi Evaluation of prognostic factors associated with outcome in dogs with multiple cutaneous mast cell tumors treated with surgery with and without adjuvant treatment: 54 cases (1998-2004)
    Marie N Mullins
    Animal Cancer Center and Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523, USA
    J Am Vet Med Assoc 228:91-5. 2006
    ..To evaluate prognostic factors associated with outcome of dogs with multiple cutaneous mast cell tumors (MCTs) treated with surgery with or without adjuvant treatment...
  50. ncbi Combination chemotherapy with L-asparaginase, lomustine, and prednisone for relapsed or refractory canine lymphoma
    Corey F Saba
    Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin Madison 53706, USA
    J Vet Intern Med 21:127-32. 2007
    ..Canine lymphoma (LSA) is responsive to initial treatment, however, it then becomes resistant to drugs in the initial protocol. New rescue protocols are needed...
  51. ncbi Successful treatment of acute tumor lysis syndrome in a dog with multicentric lymphoma
    Kathryn R Vickery
    Animal Cancer Center, Colorado State University, 300 West Drake Road, Fort Collins, CO 80523 1620, USA
    J Vet Intern Med 21:1401-4. 2007